It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The Hedgehog signaling pathway plays a crucial role in folliculogenesis; however, the association between FF-MAS oxysterol activity in folliculogenesis and the Hedgehog signaling pathway has not been revealed. The evaluation of FF-MAS activity in polycystic ovary syndrome (PCOS) with folliculogenesis disorder might provide a new approach to tackle follicular and oocyte maturation failure. The question is: does FF-MAS oxysterol affect granulosa cell (GC) proliferation? If so, is this effect facilitated through the Hedgehog pathway? To answer these questions, GCs were isolated from follicle fluids obtained from patients undergoing oocyte retrieval during in vitro fertilization (IVF) treatment. After the isolated GCs were incubated in different cell culture media, the levels of Hedgehog pathway components (SMO, Gli1) were measured by using immunohistochemical methods, cytoELISA, and qRT-PCR. Meanwhile, cell proliferation rates were determined. Significant increases (p < 0.001) in SMO and Gli1 expressions and cell proliferation were observed in the FF-MAS-treated subgroups of both PCOS and male factor participants compared to the FF-MAS deficient subgroup. Remarkably, FF-MAS positively affected the pathway components despite the pathway inhibitor cyclopamine. Although the increase in Hedgehog pathway components was slightly higher in the male factor group (MF), it was not statistically significant. In our study, we demonstrated for the first time the molecular effect of FF-MAS on human GCs in folliculogenesis. Since FF-MAS is already used in assisted reproductive techniques in animals and is known to be synthesized in the human body, it could be considered a new approach in human IVF treatments.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Erzincan Binali Yıldırım University, Faculty of Medicine, Department of Histology and Embryology, Erzincan, Turkey (GRID:grid.412176.7) (ISNI:0000 0001 1498 7262); Hacettepe University, Faculty of Medicine, Department of Histology and Embryology, Ankara, Turkey (GRID:grid.14442.37) (ISNI:0000 0001 2342 7339)
2 TOBB Economy and Technology University, Faculty of Medicine, Department of Histology and Embryology, Ankara, Turkey (GRID:grid.412749.d) (ISNI:0000 0000 9058 8063); Hacettepe University, Faculty of Medicine, Department of Histology and Embryology, Ankara, Turkey (GRID:grid.14442.37) (ISNI:0000 0001 2342 7339)
3 Ankara Etlik Lady Zübeyde Gynaecology Education and Research Hospital, Assisted Reproductive Techniques, Ankara, Turkey (GRID:grid.14442.37); Hacettepe University, Faculty of Medicine, Department of Histology and Embryology, Ankara, Turkey (GRID:grid.14442.37) (ISNI:0000 0001 2342 7339)
4 Hacettepe University, Faculty of Medicine, Department of Histology and Embryology, Ankara, Turkey (GRID:grid.14442.37) (ISNI:0000 0001 2342 7339)
5 Koç University, Faculty of Medicine, Obstetrics and Gynecology, Ankara, Turkey (GRID:grid.15876.3d) (ISNI:0000 0001 0688 7552)